Loading...
•
Jun 30, 2024
Replimune Q1 2025 Earnings Report
Replimune reported financial results for the first quarter of fiscal year 2025 and provided a corporate update.
Key Takeaways
Replimune Group, Inc. announced financial results for the fiscal first quarter ended June 30, 2024. The company is gearing up for a pre-BLA meeting with the FDA and preparing to enroll the first patient in their confirmatory trial of RP1 in anti-PD1 failed melanoma.
Preparing for pre-BLA meeting with the FDA.
Preparing to enroll the first patient in confirmatory trial of RP1 in anti-PD1 failed melanoma.
Confidence in the RP1 program is reinforced by the IGNYTE primary analysis data.
Preparing to enroll patients in a registration-directed study in uveal melanoma for RP2.
Replimune
Replimune
Forward Guidance
Based on the current operating plan, the Company believes that existing cash, cash equivalents and short-term investments, as of June 30, 2024 will enable the Company to fund operations into the second half of 2026 which includes scale up for the commercialization of RP1 in skin cancers and for working capital and general corporate purposes.